Biologic Sequencing After First-Line Anti-TNF Failure in IBD: An Umbrella Review of Meta-Analyses on Second- and Third-Line Options, Comparative Effectiveness, and Treat-to-Target Outcomes

tofacitinib - Generic mfg.

Stelara (ustekinumab) - J&J

Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim

Rinvoq (upadacitinib) - AbbVie

Entyvio (vedolizumab) - Takeda

https://acg2026.eventscribe.net/ajaxcalls/PosterInfo.asp?efp=R01PT1FGR0UyNjkyNQ&PosterID=829601&rnd=0.1830447

Adithya Chandran MBBS 1; Laiba Manzoor MBBS 2; Iman Khan MBBS 3; Abdul Basit 4; Dadullah Faiz 5; Saad Munir 6; Safia Bibi MBBS 7; Faiza Khalid MBBS 8; Prince Kusimw'iragi 9; Ashesh Das MBBS 10

Aug 29, 2026